Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus FB0012 is a specific strain of *Lactobacillus acidophilus*, a gram-positive, non-sporulating, rod-shaped bacterium commonly found as part of the natural flora of the human gut and vagina. As a probiotic, *Lactobacillus acidophilus* is widely recognized for its beneficial effects on human health, primarily by modulating the intestinal microbiota and immune system. Its mechanism of action involves producing lactic acid, which lowers the intestinal pH and inhibits the growth of pathogenic bacteria. It also produces other antimicrobial substances like bacteriocins and hydrogen peroxide, and competes with pathogens for adhesion sites and nutrients in the gut. Furthermore, *Lactobacillus acidophilus* can enhance gut barrier function, modulate host immune responses, and improve conditions such as lactose intolerance. While *Lactobacillus acidophilus* in general is used in dietary supplements and investigated for various health benefits, specific information regarding the developer, manufacturer, and primary indication for the FB0012 strain is not publicly available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus acidophilus FB0012.